Therapeutic efficacy of budesonide inhalation suspension for moderate bronchial asthma attacks as a substitute for steroid injection

Therapeutic efficacy of budesonide inhalation suspension for moderate bronchial asthma attacks as a substitute for steroid injection - Therapeutic efficacy of budesonide inhalation suspension for bronchial asthma attacks

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012722

Enrollment

100

Registered

2013-12-29

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

The mPSL group begin initial treatment with inhalation of a mixture of 0.01% procaterol hydrochloride 0.3 mL + 1% disodium cromoglycate (DSCG) 2 mL 3 times/day and intravenous administration of mPSL 1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient hospitalized for the therapy of bronchial asthma attack

Exclusion criteria

Exclusion criteria: The subjects who are diagnosed as respiratory syncytial (RS) virus infection The subjects who require oxygen administration The subjects who are not appropriate for this study, judged by medical doctor

Design outcomes

Primary

Measure	Time frame
Duration of hospitalized days, the frequency of bronchodilator inhalation and plasma cortisol levels at discharge	—

Secondary

Measure	Time frame
The Modified Pulmonary Index Score (MPIS)	—

Countries

Japan

Contacts

Public ContactNoriyuki Yanagida

National Hospital Organization Sagamihara National Hospital Department of Allergy, Clinical Research Center for Allergy and Rheumatology

foodallergy@sagamihara-hosp.gr.jp042-742-7311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026